The Secret of Cancer Cell Immortality Revealed! Telomeres, Telomerase, and Future Therapeutic Targets Transforming the World of Oncology

Telomeres and Telomerase as Targets for Cancer Therapy: From Telomere Length to Cancer Stem Cell Plasticity

 

Introduction

 

Advances in cancer research over the past several decades have demonstrated that telomeres and telomerase play crucial roles in cancer initiation, progression, and cellular survival (Blackburn, 2001; Shay & Wright, 2019). Telomeres are specialized structures located at the ends of chromosomes that protect genetic material from degradation and instability during DNA replication (de Lange, 2005). In normal somatic cells, telomeres progressively shorten with each cell division until they reach a critical length, triggering cellular senescence or programmed cell death (apoptosis) (Harley et al., 1990). In contrast, most cancer cells maintain their telomere length through the reactivation of telomerase, thereby acquiring the capacity for unlimited proliferation and cellular immortality (Kim et al., 1994; Shay & Bacchetti, 1997).

 

The schematic illustration above depicts the complex interactions among telomere length, telomerase activity, G-quadruplex structures, poly(ADP-ribosyl)ation modifications, and cancer stem cell plasticity, all of which have become major focal points in the development of modern anticancer therapies.

 

The Relationship Between Cancer and Telomere Length

Telomeres consist of repetitive DNA sequences that serve as protective caps at chromosome ends. During each round of cell division, a small portion of telomeric DNA is lost due to the limitations of the DNA replication machinery, a phenomenon known as the end-replication problem (Olovnikov, 1973; Blackburn, 2001). In normal cells, continuous telomere shortening results in:

1. Cell cycle arrest (senescence).
2. Activation of DNA damage response pathways.
3. Programmed cell death (apoptosis) (d’Adda di Fagagna et al., 2003).

However, cancer cells frequently reactivate telomerase, enabling the maintenance of telomere length. Telomerase replenishes lost telomeric DNA sequences, allowing cancer cells to proliferate indefinitely (Kim et al., 1994; Shay & Wright, 2019). As illustrated in the schematic, progressive telomere shortening ultimately leads to cellular senescence and death, whereas telomerase activation promotes telomere maintenance and supports the survival and expansion of malignant cells.

 

The Telomere Complex: Roles of TRF1 and TERRA

The biological function of telomeres is determined not only by their length but also by a variety of proteins and RNA molecules that interact with them (de Lange, 2005).

 

TRF1 (Telomeric Repeat-Binding Factor 1)

TRF1 is a critical component of the shelterin complex that regulates telomere stability and length (Palm & de Lange, 2008). This protein controls telomerase access to chromosome ends and preserves telomeric structural integrity. Disruption of TRF1 function may lead to:

• Chromosomal instability.
• Activation of DNA damage responses.
• Altered cancer cell proliferation (Martínez et al., 2009).

Consequently, TRF1 has emerged as a promising target for anticancer therapeutic strategies.

 

TERRA (Telomeric Repeat-Containing RNA)

TERRA is a long non-coding RNA transcribed from telomeric regions (Azzalin et al., 2007). It plays important roles in:

• Regulation of telomere length.
• Formation and maintenance of telomeric chromatin structures.
• Modulation of telomerase activity (Azzalin & Lingner, 2015).

Recent studies have shown that alterations in TERRA expression can influence the progression of various cancers, suggesting its potential utility as both a biomarker and a therapeutic target (Cusanelli & Chartrand, 2015).

 

From “Length” to “Structure”: Targeting G-Quadruplexes

The current paradigm of telomere research extends beyond telomere length and increasingly focuses on the three-dimensional structural organization of telomeric DNA. One of the most extensively studied structures is the G-quadruplex (G4), a secondary DNA structure formed within guanine-rich (G-rich) regions of the genome (Neidle & Balasubramanian, 2006).

Figure 1. Three-dimensional structure of a transfer RNA (tRNA) molecule represented in ribbon and nucleotide-base models.

Different colors indicate the orientation and spatial positions of nucleotides along the RNA chain. The structure exhibits the characteristic folding pattern of tRNA, forming an L-shaped three-dimensional conformation as a result of intramolecular base-pairing interactions and hydrogen bonding. One end contains the anticodon, a nucleotide sequence responsible for recognizing complementary codons on messenger RNA (mRNA) during translation, whereas the opposite end forms the acceptor stem, which serves as the attachment site for amino acids. This unique architecture enables tRNA to function as a molecular adaptor, linking the genetic information encoded in mRNA to the corresponding amino acid sequence during protein synthesis.

 

Figure 2. Mechanism of telomere maintenance and oncogene expression inhibition by G-quadruplex (G4) ligands in cancer cells.

Cancer cells maintain telomere length through two principal mechanisms: telomerase activation and the Alternative Lengthening of Telomeres (ALT) pathway. G4 ligands promote the formation and stabilization of G-quadruplex structures within telomeric regions and gene promoters, thereby inhibiting telomerase activity, inducing telomere shortening, and suppressing the transcription of several oncogenes, including TERT, C-MYC, BCL2, KRAS, and VEGF. In cells that rely on the ALT pathway, G4 ligands can also stabilize G-loop structures, which may serve as promising therapeutic targets for anticancer interventions. Overall, the formation and stabilization of G-quadruplex structures contribute to the inhibition of cancer cell proliferation by disrupting telomere maintenance mechanisms and modulating oncogene expression.

 

Figure 3. Structure and topology of G-quadruplexes (G4) formed by guanine-rich nucleic acid sequences.

The upper panel illustrates the formation of a G-tetrad, a planar structure composed of four guanine bases connected through Hoogsteen hydrogen bonds and stabilized by the presence of a central monovalent or divalent cation (M⁺). Stacking of multiple G-tetrads gives rise to a stable G-quadruplex (G4) structure. G-quadruplexes may form through intramolecular folding, in which a single nucleic acid strand folds upon itself to generate a G4 structure, or through intermolecular association, where two or more nucleic acid strands assemble to form a G4 complex. The lower panel depicts the major G-quadruplex topologies, including parallel, antiparallel, and hybrid (mixed) conformations, which are distinguished by strand orientation (indicated by arrows) and the arrangement of loop regions connecting guanine-rich segments. These structural variations influence the stability, biological functions, and molecular recognition properties of G-quadruplexes.

G-Quadruplex Formation and Its Therapeutic Implications

The formation of G-quadruplex structures can:

• Inhibit telomerase activity.
• Interfere with DNA replication in cancer cells.
• Activate DNA damage signaling pathways.
• Suppress tumor proliferation (Mergny & Sen, 2019).

Because most cancer cells depend on telomerase activity for unlimited proliferation, stabilization of G-quadruplex structures using small molecules has emerged as a highly promising therapeutic strategy (Neidle, 2017). This approach enables a more specific inhibition of cancer growth compared with conventional chemotherapy.

 

Poly(ADP-ribosyl)ation and Tankyrase as Emerging Therapeutic Targets

The above scheme also highlights the importance of poly(ADP-ribosyl)ation in the regulation of telomeres and cancer signaling pathways (Lehtiö et al., 2013). A key protein involved in this process is Tankyrase, an enzyme belonging to the PARP (Poly ADP-ribose Polymerase) family (Smith et al., 1998).

 

1. Telomere Regulation

Tankyrase modifies telomeric proteins through poly(ADP-ribosyl)ation, thereby influencing telomerase access to chromosome ends (Cook et al., 2002).

Elevated tankyrase activity can:

• Promote telomere elongation.
• Support cancer cell immortality.
• Facilitate tumor growth (Seimiya et al., 2005).

 

2. Regulation of the Wnt/β-Catenin Pathway

Tankyrase also plays a critical role in regulating Axin, an essential component of the Wnt signaling pathway (Huang et al., 2009).

When tankyrase is active:

• Axin undergoes degradation.
• β-catenin becomes stabilized.
• The Wnt signaling pathway is activated.
• Cancer cell proliferation increases (Lau et al., 2013).

Therefore, the development of tankyrase inhibitors is expected to provide dual therapeutic benefits by simultaneously inhibiting telomere maintenance and suppressing tumor growth mediated through the Wnt/β-catenin pathway.

 

Tumor Plasticity and Heterogeneity

One of the greatest challenges in cancer therapy is the presence of cancer stem cells (CSCs) (Batlle & Clevers, 2017).

Cancer stem cells possess the ability to:

• Self-renew.
• Differentiate into various tumor cell types.
• Survive chemotherapy and radiotherapy.
• Initiate tumor recurrence following treatment (Reya et al., 2001).

The scheme above illustrates the relationship between telomerase activity and the self-renewal capacity of cancer stem cells. High telomerase activity helps maintain the regenerative potential of CSCs, enabling cancer cell populations to persist over time (Flores et al., 2008).

 

Drug Resistance and Tumor Recurrence

Although anticancer therapies can eliminate the majority of tumor cells, a small population of CSCs often survives treatment. These surviving cells may subsequently regenerate tumors that are more resistant to therapy (Batlle & Clevers, 2017).

This phenomenon is associated with:

• Drug resistance.
• Tumor recurrence.
• Tumor heterogeneity (Meacham & Morrison, 2013).

Consequently, the identification of CSC-specific molecular targets has become a major focus in the development of next-generation cancer therapies.

 

Integration of Multiple Telomere-Based Therapeutic Targets

 

Three major directions have emerged in the development of telomere-based cancer therapies:

1. Targeting G-Quadruplex Structures

• Inhibition of telomerase activity.
• Disruption of cancer DNA replication.
• Induction of tumor cell death.

2. Inhibition of Tankyrase and Poly(ADP-ribosyl)ation

• Reduction of telomere elongation.
• Suppression of Wnt/β-catenin signaling.
• Inhibition of cancer cell proliferation.

3. Targeting Cancer Stem Cells

• Reduction of self-renewal capacity.
• Suppression of drug resistance.
• Prevention of tumor recurrence.

This multimodal therapeutic strategy is expected to provide greater efficacy than conventional approaches that primarily target tumor cell proliferation (Shay & Wright, 2019).

 

CONCLUSION

 

Telomeres and telomerase are fundamental components of cancer biology and have become among the most promising targets for anticancer therapy (Blackburn, 2001; Shay & Wright, 2019). Modern research has expanded beyond the study of telomere length alone to encompass G-quadruplex structures, regulation by TERRA and TRF1, tankyrase activity, and their interactions with cancer stem cells.

A deeper understanding of these mechanisms provides new opportunities for the development of more specific, effective, and less toxic anticancer therapies. In the future, combinations of telomerase inhibitors, G-quadruplex stabilizers, tankyrase inhibitors, and therapies targeting cancer stem cells may represent a powerful strategy for overcoming drug resistance and preventing tumor recurrence.

 

DAFTAR PUSTAKA

 

Azzalin, C.M., Reichenbach, P., Khoriauli, L., Giulotto, E., & Lingner, J. (2007). Telomeric repeat-containing RNA and RNA surveillance factors at mammalian chromosome ends. Science, 318(5851), 798–801.

 

Azzalin, C.M., & Lingner, J. (2015). Telomeres: the silence is broken. Cell Cycle, 14(7), 998–1000.

 

Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. Nature Medicine, 23(10), 1124–1134.

 

Blackburn, E.H. (2001). Switching and signaling at the telomere. Cell, 106(6), 661–673.

 

Cook, B.D., Dynek, J.N., Chang, W., Shostak, G., & Smith, S. (2002). Role for the related poly(ADP-ribose) polymerases tankyrase 1 and 2 at human telomeres. Molecular and Cellular Biology, 22(1), 332–342.

 

Cusanelli, E., & Chartrand, P. (2015). Telomeric noncoding RNA: Telomeric repeat-containing RNA in telomere biology. Wiley Interdisciplinary Reviews RNA, 6(4), 407–419.

 

d’Adda di Fagagna, F., Reaper, P.M., Clay-Farrace, L., et al. (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 194–198.

 

de Lange, T. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes & Development, 19(18), 2100–2110.

 

Flores, I., Cayuela, M.L., & Blasco, M.A. (2008). Effects of telomerase and telomere length on epidermal stem cell behavior. Science, 309(5738), 1253–1256.

 

Harley, C.B., Futcher, A.B., & Greider, C.W. (1990). Telomeres shorten during ageing of human fibroblasts. Nature, 345, 458–460.

 

Huang, S.M.A., Mishina, Y.M., Liu, S., et al. (2009). Tankyrase inhibition stabilizes Axin and antagonizes Wnt signalling. Nature, 461, 614–620.

 

Kim, N.W., Piatyszek, M.A., Prowse, K.R., et al. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science, 266(5193), 2011–2015.

 

Lau, T., Chan, E., Callow, M., et al. (2013). A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Research, 73(10), 3132–3144.

 

Lehtiö, L., Collins, R., van den Berg, S., et al. (2013). Tankyrases: structure, function and therapeutic implications in cancer. Current Pharmaceutical Design, 19(23), 6472–6488.

 

Martínez, P., Thanasoula, M., Muñoz, P., et al. (2009). Increased telomere fragility and fusions resulting from TRF1 deficiency. EMBO Journal, 28(13), 1819–1830.

 

Meacham, C.E., & Morrison, S.J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature, 501, 328–337.

 

Mergny, J.L., & Sen, D. (2019). DNA quadruple helices in nanotechnology. Chemical Reviews, 119(10), 6290–6325.

 

Neidle, S. (2017). Quadruplex nucleic acids as targets for anticancer therapeutics. Nature Reviews Chemistry, 1, 0041.

 

Neidle, S., & Balasubramanian, S. (2006). Quadruplex Nucleic Acids. Cambridge: Royal Society of Chemistry.

 

Olovnikov, A.M. (1973). A theory of marginotomy. Journal of Theoretical Biology, 41(1), 181–190.

 

Palm, W., & de Lange, T. (2008). How shelterin protects mammalian telomeres. Annual Review of Genetics, 42, 301–334.

 

Reya, T., Morrison, S.J., Clarke, M.F., & Weissman, I.L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105–111.

 

Seimiya, H., Muramatsu, Y., Ohishi, T., & Tsuruo, T. (2005). Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell, 7(1), 25–37.

 

Shay, J.W., & Bacchetti, S. (1997). A survey of telomerase activity in human cancer. European Journal of Cancer, 33(5), 787–791.

 

Shay, J.W., & Wright, W.E. (2019). Telomeres and telomerase: three decades of progress. Nature Reviews Genetics, 20(5), 299–309.

 

#Telomerase
#CancerTherapy
#Telomer
#CancerStemCells
#CancerBiology